Gossamer Bio Inc. [NASDAQ: GOSS] stock went on an upward path that rose over 2.00% on Friday, amounting to a one-week price decrease of less than -26.67%. The company report on October 13, 2020 that Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis.
– Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups -.
– Statistically significant improvements in key secondary endpoint of time to first asthma worsening of 28% and 30% observed for 20 mg and 60 mg doses of GB001, respectively; 23% improvement observed in 40 mg group -.
Over the last 12 months, GOSS stock dropped by -39.95%. The average equity rating for GOSS stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $719.61 million, with 66.60 million shares outstanding and 48.36 million shares in the current float. Compared to the average trading volume of 686.40K shares, GOSS stock reached a trading volume of 1293386 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Gossamer Bio Inc. [GOSS]:
H.C. Wainwright have made an estimate for Gossamer Bio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 29, 2020. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on April 22, 2020, representing the official price target for Gossamer Bio Inc. stock. Previously, the target price had yet another raise to $21, while Barclays analysts kept a Overweight rating on GOSS stock.
The Average True Range (ATR) for Gossamer Bio Inc. is set at 1.04 The Price to Book ratio for the last quarter was 1.53, with the Price to Cash per share for the same quarter was set at 8.08.
GOSS Stock Performance Analysis:
Gossamer Bio Inc. [GOSS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -26.67. With this latest performance, GOSS shares dropped by -24.02% in over the last four-week period, additionally sinking by -21.68% over the last 6 months – not to mention a drop of -39.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GOSS stock in for the last two-week period is set at 34.49, with the RSI for the last a single of trading hit 31.61, and the three-weeks RSI is set at 37.34 for Gossamer Bio Inc. [GOSS]. The present Moving Average for the last 50 days of trading for this stock 12.85, while it was recorded at 10.44 for the last single week of trading, and 12.87 for the last 200 days.
Insight into Gossamer Bio Inc. Fundamentals:
Return on Total Capital for GOSS is now -59.82, given the latest momentum, and Return on Invested Capital for the company is -59.31. Return on Equity for this stock declined to -63.18, with Return on Assets sitting at -54.14. When it comes to the capital structure of this company, Gossamer Bio Inc. [GOSS] has a Total Debt to Total Equity ratio set at 11.22. Additionally, GOSS Total Debt to Total Capital is recorded at 10.09, with Total Debt to Total Assets ending up at 9.27. Long-Term Debt to Equity for the company is recorded at 10.55, with the Long-Term Debt to Total Capital now at 9.49.
Reflecting on the efficiency of the workforce at the company, Gossamer Bio Inc. [GOSS] managed to generate an average of -$1,054,427 per employee.Gossamer Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 22.10 and a Current Ratio set at 22.10.
GOSS Stock EPS
With the latest financial reports released by the company, Gossamer Bio Inc. posted -0.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.69/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -15.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GOSS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gossamer Bio Inc. go to 5.20%.
Gossamer Bio Inc. [GOSS] Insider Position Details
There are presently around $0 million, or 81.00% of GOSS stock, in the hands of institutional investors. The top three institutional holders of GOSS stocks are: HILLHOUSE CAPITAL ADVISORS, LTD. with ownership of 7,420,974, which is approximately 25.534% of the company’s market cap and around 0.10% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 5,157,951 shares of the stock with an approximate value of $49.93 million in GOSS stocks shares; and VANGUARD GROUP INC, currently with $47.26 million in GOSS stock with ownership of nearly 28.065% of the company’s market capitalization.
Positions in Gossamer Bio Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where institutional holders increased their position in Gossamer Bio Inc. [NASDAQ:GOSS] by around shares. Additionally, investors decreased positions by around shares, while investors held positions by with shares. The mentioned changes placed institutional holdings at shares, according to the latest SEC report filing. GOSS stock had new institutional investments in for a total of shares, while institutional investors sold positions of shares during the same period.